Inotropes historically all increased intra-cellular calcium levels and they commonly caused
intracellular Ca2+ overload and triggered malignant arrhythmias. The myosin activators …

Heart failure continues to be a major global health problem with a pronounced impact on
morbidity and mortality and very limited drug treatment options especially with regard to …

Despite the rising prevalence of HF, new evidence-based novel therapies for patients with
worsening HF remain lacking, eg, safe inotropic therapies. Traditional inotropes increase …

Heart failure became a leading cause of mortality in the past decades with a progressively
increasing prevalence. Its current therapy is restricted largely to the suppression of the …

Selective cardiac myosin activators constitute a new class of drugs capable of increasing
cardiac contractility independently of intracellular calcium concentrations. In the GALACTIC …

Systolic heart failure remains a leading cause of death and disability, and available
pharmacologic treatments for heart failure are limited in both safety and effectiveness …

Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac
contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to …

Omecamtiv mecarbil (OM) is a positive cardiac inotrope in phase-3 clinical trials for
treatment of heart failure. Although initially described as a direct myosin activator …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Aims Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and
morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments …